We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Molecular Test Identifies Acute Transplant Rejection

By LabMedica International staff writers
Posted on 25 Nov 2014
Print article
Fluidigm\'s BioMark HD and EP1 platform with Digital Array Integrated Fluidic Circuits for quantitative real-time polymerase chain reaction
The BioMark HD and EP1 platform with Digital Array Integrated Fluidic Circuits for quantitative real-time polymerase chain reaction (Photo courtesy of Fluidigm)
The development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a critical need in renal transplantation, as acute rejection (AR) increases the risk for chronic graft injury and failure.

Acute rejection after kidney transplantation occurs in about 15% to 20% of patients despite immunosuppressive therapy and rejection is usually heralded by an increase in the patient's serum creatinine which is a marker of kidney function, and a kidney biopsy is then performed to confirm whether rejection is taking place.

Scientists at the University of California (San Francisco, CA, USA) working with an international team used 558 peripheral blood (PB) samples from 438 adult and pediatric renal transplant patients from eight renal transplant centers in the United States, Mexico, and Spain and enrolled between 2005 and 2012 to develop a quantitative real-time polymerase chain reaction (qPCR) test. They developed the test in 143 samples from adults with and without acute rejection as determined by kidney biopsy, and then finalized and validated the test in three cohorts of patients.

Total ribonucleic acid (RNA) was extracted using the column-based method kits and was measured for RNA integrity using the RNA 6000 Nano LabChip Kit on a 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA). Microfluidic qPCR was performed on the 96.96 dynamic array and the chip loaded via the HX IFC Controller and performing the qPCR in the BioMark qPCR platform (Fluidigm; South San Francisco, CA, USA).

The team evaluated the differential expression of 10 out of 43 genes, selecting the same ten genes that have been validated as diagnostic for AR in PB using standardized clinical trial sample collection and processing protocols. To improve the diagnostic accuracy for AR in the 143 adult samples, various statistical modeling methods were used to include an additional seven genes which improved the accuracy of the gene panel for discriminating AR from No-AR samples, for a final selection of 17 genes. The assay was called kSORT and was able to classify patients as high risk versus low risk for AR. The kSORT assay was able to detect AR in blood independent of age, time post-transplantation, and sample source without additional data normalization.

The authors concluded that the kSORT assay is a simple, robust, and clinically applicable blood test. They are using kSORT in a prospective observational trial as well as a second prospective, randomized, double-blinded clinical interventional trial, which will establish how kSORT can be used serially post-transplant to complement current clinical practice guidelines for stratifying patient immune risk, medication load, and requirement for biopsy. The study was published on November 11, 2014, in the journal Public Library of Science Medicine.

Related Links:

University of California
Agilent Technologies
Fluidigm


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.